open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29
Get Citation

Antiangiogenic treatment in patients with renal cell carcinoma

Jakub Żołnierek, Cezary Szczylik

open access

Vol 5, Supp. A (2009)
suplement
Published online: 2009-04-29

Abstract

Due to its increasing incidence, stilth course and resistance to classic pharmacotherapy, renal cell carcinoma (RCC) is a specific and important clinical problem. Advanced laboratory techniques helped to identify the potent role of membrane receptors for growth factors and cascade of triggered molecular reactions that lead to phenotypic changes from normal to neoplastic, uncontrolled proliferation and angiogenesis. Due to its high metabolic activity, formation of new blood vessels within the tumor burden is crucial for the development of renal cell carcinoma. Main points for signals transduction in angiogenesis are VEGF-dependent and PDGF- -dependent pathways. Agents targeting certain elements of these chain reactions linking cell membrane and the nucleus are effective in therapy of patients with metastatic renal cell carcinoma.

Abstract

Due to its increasing incidence, stilth course and resistance to classic pharmacotherapy, renal cell carcinoma (RCC) is a specific and important clinical problem. Advanced laboratory techniques helped to identify the potent role of membrane receptors for growth factors and cascade of triggered molecular reactions that lead to phenotypic changes from normal to neoplastic, uncontrolled proliferation and angiogenesis. Due to its high metabolic activity, formation of new blood vessels within the tumor burden is crucial for the development of renal cell carcinoma. Main points for signals transduction in angiogenesis are VEGF-dependent and PDGF- -dependent pathways. Agents targeting certain elements of these chain reactions linking cell membrane and the nucleus are effective in therapy of patients with metastatic renal cell carcinoma.
Get Citation

Keywords

renal cancer; angiogenesis; bevacizumab

About this article
Title

Antiangiogenic treatment in patients with renal cell carcinoma

Journal

Oncology in Clinical Practice

Issue

Vol 5, Supp. A (2009)

Pages

32-38

Published online

2009-04-29

Keywords

renal cancer
angiogenesis
bevacizumab

Authors

Jakub Żołnierek
Cezary Szczylik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl